Biosystems engineering of prokaryotes with tumor-killing capacities

Kalyoncu, E.
Olmez, T. T.
Ozkan, A. D.
Sarioglu, O. F.
Journal Title
Journal ISSN
Volume Title
Bentham Science Publishers Ltd.

Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.

Bifidobacterium, Cancer therapy, Clostridium, Live vaccines, Prodrug cleavage, Salmonella, Synthetic biology, Antineoplastic agent, Cytotoxic factor, Drug carrier, Flucytosine, Fluorouracil, Ganciclovir, Live vaccine, Probiotic agent, Tretazicar, Unclassified drug, Vnp 20009, Antibiotic therapy, Antineoplastic activity, Article, Bacterial membrane, Bacterial strain, Bifidobacterium, Cancer diagnosis, Cancer recurrence, Cancer therapy, CD8+ T lymphocyte, Cell infiltration, Clostridium, Colony forming unit, Drug activation, Drug delivery system, Escherichia, Gene transfer, Genetic engineering, Immune response, Immunogenicity, Metastasis, Natural killer T cell, Nonhuman, Oxygen concentration, Phase 2 clinical trial (topic), Priority journal, Prokaryote, Salmonella, Target cell, Tumor microenvironment, Type III secretion system, Animal, Bacterium, Biological therapy, Cytology, Genetics, Human, Metabolism, Microbiology, Neoplasms, Pathophysiology, Prokaryotic cell, Animals, Bacteria, Biological therapy, Humans, Neoplasms, Prokaryotic cells